First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
20.05
+1.95 (10.77%)
At close: Apr 28, 2026, 4:00 PM EDT
19.56
-0.49 (-2.44%)
After-hours: Apr 28, 2026, 7:58 PM EDT
TRAX Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TRAX stock have an average target of 38.4, with a low estimate of 30 and a high estimate of 46. The average target predicts an increase of 91.52% from the current stock price of 20.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TRAX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 |
|---|---|
| Strong Buy | 2 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +49.63% | Apr 28, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $46 | Buy | Initiates | $46 | +129.43% | Apr 24, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $31 | Buy | Initiates | $31 | +54.61% | Apr 23, 2026 |
| Barclays | Barclays | Buy Initiates $40 | Buy | Initiates | $40 | +99.50% | Apr 22, 2026 |
| UBS | UBS | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +124.44% | Apr 21, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.